Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

It’s an odd time for the federal government to effectively offer its imprimatur for marijuana, as the White House seems to be ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Australia's medicine watchdog has issued another safety alert for contaminated Ayurvedic medicines. So what do consumers need ...

According to guides and other players in the sport, Minnesotans are snapping up gear, booking trips and winter fishing ...

The move to reclassify cannabis from a Schedule I to a Schedule III drug could spark new studies into pain, aging and women's health, Dr. Staci Gruber tells GBH's All Things Considered.

Since California first legalized medicinal cannabis in 1996, the U.S. pot industry has morphed into a $40 billion behemoth.

TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

Since California first legalized medicinal cannabis in 1996, the U.S. pot industry has morphed into a $40 billion behemoth. Weed is now legal in 24 states for recreational purposes and in 40 for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) ...